Further confusing came a response from Moderna president Stephen Hoge as to whether a third or more dose of the vaccine would be necessary. It seems that the answer to this question still remains unclear.
modern head Stephen Hogefrom the United States third A statement came that did not explain much about the discussion of whether or not he needed more doses of vaccine.
3. for the growing debate over whether to get the last dose of vaccine or more if needed Yahoo Finance“We really don’t know,” Hoge said, adding, “This is a scientific question we’re all trying to solve right now.” In addition, it is still unclear who will benefit most from the extra dose.
Experts are nervous about the upcoming winter months:
According to Hoge, if an additional dose proves to provide better protection, it seems highly likely that a third dose will be administered in late autumn and winter, when respiratory diseases and thus cases are on the rise.
Health experts have been dreading the upcoming cold weather for some time, which they think will once again explode in cases across the country. Considering the high vaccination rates, the severity of these cases can be quite mild; However Delta variant continues to prove to cause an explosion of cases, and in addition, by the end of the year your new variants There is also the fact that it can originate and spread. For this reason, some experts believe that the current vaccine level is sufficient and that thanks to the vaccine, COVID-19 He believes that memory cells that learn how to fight with it should be trusted. However, some experts argue that antibody levels at their highest after vaccination should be considered to determine when to supplement.
Hoge said, “We think that the debate about whether to base memory cells or antibodies is wrong. Each both are important.He stated that he thinks that both perspectives should be taken into account.
They are awaiting FDA approval for the booster dose:
According to data released Wednesday modernfrom first dose compared to one year later 8 months later provides better protection against exploding cases; however, the most benefit is for the booster dose. FDAThe immunosuppressed and the elderly who have already authorized will see it.
In addition, Moderna, which corresponds to half the original dose 50 micrograms It is also trying to get FDA approval for the booster dose.
In addition to all this, Moderna is considering increasing potential production as a result of a lower booster dose.
RELATED NEWS
The Vaccine That Reduces the Risk of Hospitalization Due to COVID-19 The Most Announced
Since COVID-19 entered the vaccine industry, the company’s once-small biotech stock has skyrocketed. Hoge said about this situation, “As a company, we produce diligently, “he said and”We’re doing as much as we can, and we’ve done it for most of the year – and we’ll do it for most of next year. We are trying to scale up and invest in production to produce more doses. ‘ he added to his words.